We are live on ! Find out more
RPRX icon

Royalty Pharma
RPRX

487 hedge funds and large institutions have $11.6B invested in Royalty Pharma in 2025 Q3 according to their latest regulatory filings, with 92 funds opening new positions, 206 increasing their positions, 131 reducing their positions, and 53 closing their positions.

New
Increased
Maintained
Reduced
Closed

440% more call options, than puts

Call options by funds: $50.3M | Put options by funds: $9.31M

74% more first-time investments, than exits

New positions opened: 92 | Existing positions closed: 53

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

57% more repeat investments, than reductions

Existing positions increased: 206 | Existing positions reduced: 131

7% more funds holding

Funds holding: 455 → 487 (+32)

5.29% less ownership

Funds ownership: 81.34% → 76.05% (-5.3%)

6% less capital invested

Capital invested by funds: $12.4B → $11.6B (-$760M)

Holders
487
Holders Change
+32
Holders Change %
+7.03%
% of All Funds
6.39%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
92
Increased
206
Reduced
131
Closed
53
Calls
$50.3M
Puts
$9.31M
Net Calls
+$41M
Net Calls Change
-$22.7M

Top Buyers

1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$216M
2
Capital International Investors
Capital International Investors
California
+$193M
3
Jane Street
Jane Street
New York
+$86.6M
4
DAM
Dorsey Asset Management
Illinois
+$85.1M
5
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT)
United Kingdom
+$79.1M

Top Sellers

1
Vanguard Group
Vanguard Group
Pennsylvania
-$921M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$448M
3
Viking Global Investors
Viking Global Investors
Connecticut
-$93.6M
4
JAM
Jupiter Asset Management
United Kingdom
-$89M
5
Morgan Stanley
Morgan Stanley
New York
-$88.3M
Name Holding Trade Value Shares
Change 		Change in
Stake
SSA
276
Sierra Summit Advisors
Nevada
$698K +$15.2K +420 +2%
Assenagon Asset Management
277
Assenagon Asset Management
Luxembourg
$662K +$39.2K +1,083 +6%
Carson Wealth (CWM LLC)
278
Carson Wealth (CWM LLC)
Nebraska
$656K +$10.2K +281 +2%
MSRPS
279
Maryland State Retirement & Pension System
Maryland
$645K – – –
Holocene Advisors
280
Holocene Advisors
New York
$645K +$282K +7,779 +74%
BCI
281
Brinker Capital Investments
Pennsylvania
$630K +$125K +3,450 +24%
IMCOOI
282
Investment Management Corp of Ontario (IMCO)
Canada
$630K +$319K +8,823 +98%
PPW
283
PACK Private Wealth
Minnesota
$614K – – –
LA
284
LBP AM
France
$605K -$30.7K -847 -5%
MWM
285
Maridea Wealth Management
New York
$604K +$597K +16,492 New
VFA
286
Values First Advisors
Tennessee
$603K +$62.3K +1,721 +11%
MAS
287
Meeder Advisory Services
Ohio
$603K -$6.55K -181 -1%
FFM
288
Fullerton Fund Management
Singapore
$602K +$202K +5,579 +49%
SACTSONJ
289
Supplemental Annuity Collective Trust (SACT) of New Jersey
New Jersey
$600K – – –
HHGC
290
Hunting Hill Global Capital
New York
$562K – – –
OAC
291
OMERS Administration Corp
Ontario, Canada
$561K – – –
SOMRS
292
State of Michigan Retirement System
Michigan
$561K – – –
ProShare Advisors
293
ProShare Advisors
Maryland
$544K -$12K -332 -2%
ASN
294
Advisory Services Network
Georgia
$529K -$7.67K -212 -1%
AGM
295
Alpine Global Management
New York
$513K +$526K +14,541 New
US Bancorp
296
US Bancorp
Minnesota
$509K +$145 +4 +0%
ECM
297
Evergreen Capital Management
Washington
$506K +$3K +83 +0.6%
QI
298
Qtron Investments
Massachusetts
$502K +$106K +2,938 +26%
Principal Financial Group
299
Principal Financial Group
Iowa
$501K -$76.6K -2,116 -13%
ACA
300
Aptus Capital Advisors
Alabama
$497K +$122K +3,369 +31%
10 11
12
13 14

RPRX Hedge Fund Activity: Q3 2025 in Review

487 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Royalty Pharma (RPRX) for Q3 2025, worth a combined $11.6B — down 6.2% from $12.4B a quarter earlier.

Buyers outnumbered sellers: 92 funds opened new RPRX positions and 53 closed out — a net gain of 39 holders — while 206 added to existing stakes and 131 trimmed.

The largest buyer was Adage Capital Partners, adding an estimated $216M. The largest seller was Vanguard Group, cutting an estimated $921M.

  • 487 institutional investors held Royalty Pharma (RPRX) as of Q3 2025, up from 455 in Q2 2025.
  • Funds reported $11.6B of Royalty Pharma stock for Q3 2025, down 6.2% quarter-over-quarter.
  • 92 funds opened new Royalty Pharma positions in Q3 2025 and 53 closed out, a net change of +39 holders.
  • The largest Royalty Pharma buyer in Q3 2025 was Adage Capital Partners, an estimated $216M added.
  • The largest Royalty Pharma seller in Q3 2025 was Vanguard Group, an estimated $921M sold.

Based on aggregated 13F filings for Q3 2025.